Welcome Guest! You are here: Home » Health

Current methods for reporting toxicities in cancer clinical trials falling short: Study

According to the results, the strongest impact on quality-of-life came from cumulative toxicities, regardless of the grade

Wednesday December 19, 2018 10:34 PM, ummid.com News Network

Cancer Clinical trial

Plymouth Meeting (Pennsylvania): New research from Europe, published in the December 2018 issue of JNCCN - Journal of the National Comprehensive Cancer Network, finds that quality-of-life for people with cancer is reduced by an accumulation of low-level toxicities just as much as it is from high-level adverse events.

Additionally, patient-reported outcomes were more likely to reflect the impact on a patient's physical well-being than those reported by their doctor, the research said.

"Incorporating patient-reported toxicity into routine cancer care will help make sure people with cancer get high-quality care with better symptom detection and management," explained Claudia Schuurhuizen, MD, Amsterdam UMC Cancer Center Amsterdam.

"These patient-reported outcomes appear to have a better correlation to patient quality-of-life. Our results also suggest that clinicians shouldn't lose sight of lower grade adverse events. We want physicians to be more aware of how addressing lower grade toxicities can be just as important as higher ones for optimizing physical health status", she added.

Clinicians grade toxicity using National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) on a five-point scale, with higher numbers being worse and grade three and four generally indicating a need for clinical action. For example, in the case of vomiting, grade 1 correlates to one-to-two episodes of vomiting in 24 hours; grade 2 would be three-to-five episodes; grade 3 means more than six episodes, requiring a feeding tube or hospitalization; and grade 4 would be life-threatening consequences that need urgent intervention.

For this study, the researchers looked at 184 patients who were enrolled in a multicenter phase III randomized trial for patients with metastatic castrate-naïve prostate cancer between October 2004 and December 20081. Each patient completed quality-of-life assessments before treatment, as well as at three and six months in. Separate toxicity data were reported by both the patients and their clinicians.

According to the results, the strongest impact on quality-of-life came from cumulative toxicities, regardless of the grade. The researchers also found that patient-reported toxicity scores were more associated with quality-of-life outcomes than clinician-reported scores.

"This study clearly demonstrates that patients self-report higher rates of toxicities when independently queried, compared with clinician-elicited toxicities during office visits," said Terry S. Langbaum, Administrative Director, The Comprehensive Transplant Center, Johns Hopkins, and Patient Advocate, NCCN Guidelines® Panel for Survivorship.

"This may be due to a reluctance, on the part of patients, to 'complain' to their clinicians in a face-to-face encounter, especially when the symptoms are sensitive, such as impact on sexual function", Terry said.

"Additionally, the significant differences in reporting may be due to less thorough inquiry on the part of the clinicians, who may be rushed for time during visits. If a full understanding of the impact of toxicities on quality-of-life is the goal, this study demonstrates that patients can self-report and grade their toxicities more completely in a setting independent of the office visit than clinicians can during a clinical encounter", he said.

For all the latest News, Opinions and Views, download ummid.com App.

Select Language To Read in Urdu, Hindi, Marathi or Arabic.

Share this page

 Post Comments
Note: By posting your comments here you agree to the terms and conditions of www.ummid.com